JP2018531961A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531961A5
JP2018531961A5 JP2018521382A JP2018521382A JP2018531961A5 JP 2018531961 A5 JP2018531961 A5 JP 2018531961A5 JP 2018521382 A JP2018521382 A JP 2018521382A JP 2018521382 A JP2018521382 A JP 2018521382A JP 2018531961 A5 JP2018531961 A5 JP 2018531961A5
Authority
JP
Japan
Prior art keywords
composition
stroke
hours
onset
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018521382A
Other languages
English (en)
Japanese (ja)
Other versions
JP6889493B2 (ja
JP2018531961A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/058804 external-priority patent/WO2017075013A1/en
Publication of JP2018531961A publication Critical patent/JP2018531961A/ja
Publication of JP2018531961A5 publication Critical patent/JP2018531961A5/ja
Application granted granted Critical
Publication of JP6889493B2 publication Critical patent/JP6889493B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018521382A 2015-10-26 2016-10-26 脳卒中からの回復のための方法および組成物 Active JP6889493B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562246574P 2015-10-26 2015-10-26
US62/246,574 2015-10-26
PCT/US2016/058804 WO2017075013A1 (en) 2015-10-26 2016-10-26 Methods and compositions for recovery from stroke

Publications (3)

Publication Number Publication Date
JP2018531961A JP2018531961A (ja) 2018-11-01
JP2018531961A5 true JP2018531961A5 (US07981874-20110719-C00313.png) 2019-12-05
JP6889493B2 JP6889493B2 (ja) 2021-06-18

Family

ID=58631977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018521382A Active JP6889493B2 (ja) 2015-10-26 2016-10-26 脳卒中からの回復のための方法および組成物

Country Status (5)

Country Link
EP (1) EP3368040B1 (US07981874-20110719-C00313.png)
JP (1) JP6889493B2 (US07981874-20110719-C00313.png)
KR (1) KR20180101322A (US07981874-20110719-C00313.png)
CN (1) CN108348524A (US07981874-20110719-C00313.png)
WO (1) WO2017075013A1 (US07981874-20110719-C00313.png)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3077499C (en) 2017-10-05 2021-09-21 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
WO2020108659A1 (zh) * 2018-11-30 2020-06-04 上海医药集团股份有限公司 含氮杂环类化合物及其组合物、制备方法和应用
JP7384341B1 (ja) 2023-07-07 2023-11-21 学校法人冬木学園 脳卒中患者の身体の痛みの改善を目的とするリハビリテーションの効果を予測するための方法、及び、システム

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
CA2479737C (en) * 2002-03-20 2011-05-24 Elan Pharma International Ltd. Nanoparticulate compositions of map kinase inhibitors
AU2003220553A1 (en) * 2002-03-29 2003-10-20 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
EP2296653B1 (en) * 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9816336B2 (en) 2014-07-08 2017-11-14 Halliburton Energy Services, Inc. Real time conformance
JP6660369B2 (ja) * 2014-07-09 2020-03-11 イーアイピー ファーマ, エルエルシー 神経障害を治療する方法

Similar Documents

Publication Publication Date Title
JP2018531961A5 (US07981874-20110719-C00313.png)
JP2015512406A5 (US07981874-20110719-C00313.png)
MX2020003462A (es) Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
JP2015522630A5 (US07981874-20110719-C00313.png)
JP2012193216A5 (US07981874-20110719-C00313.png)
JP2010248252A5 (US07981874-20110719-C00313.png)
AR082150A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
JP2015038149A5 (US07981874-20110719-C00313.png)
JP2018520189A5 (US07981874-20110719-C00313.png)
JP2009514874A5 (US07981874-20110719-C00313.png)
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
JP2014198723A5 (US07981874-20110719-C00313.png)
JP2017503014A5 (US07981874-20110719-C00313.png)
JP2016539125A5 (US07981874-20110719-C00313.png)
JP2013518914A5 (US07981874-20110719-C00313.png)
JP2016537338A5 (US07981874-20110719-C00313.png)
JP2017533220A5 (US07981874-20110719-C00313.png)
JP2020534270A5 (US07981874-20110719-C00313.png)
WO2016168553A8 (en) Deuterated obeticholic acid
PH12021551541A1 (en) Compositions and methods for treating neurodegenerative disorders
WO2015116856A3 (en) Farnesoid x receptor antagonists
JP2018521007A5 (US07981874-20110719-C00313.png)
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
WO2019194773A3 (en) The combination comprising linagliptin and metformin
JP2016512247A5 (US07981874-20110719-C00313.png)